NCT01558947

Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer

Peri-operative Chemotherapy With ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine + Cisplatin) in the Treatment of Advanced Gastric Cancer: a Randomized, Multicenter, Parallel Control

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and the effect of perioperative chemotherapy in the treatment of advanced gastric cancer.

Detailed description

To evaluate the security and the relapse-free survival time/rate(1,2,3 yrs) of perioperative chemotherapy with ECX (epirubicin + cisplatin + capecitabine) and XP (capecitabine + cisplatin）in advanced gastric cancer

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
DRUG	Peri-operative chemotherapy of ECX	Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4\~6 weeks after surgery.
DRUG	Peri-operative chemotherapy of XP	Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4\~6 weeks after surgery.

Timeline

• Start date: 2011-01-01
• Primary completion: 2012-12-01
• Completion: 2013-06-01
• First posted: 2012-03-20
• Last updated: 2012-03-20

Locations

1 site across 1 country: China